Marksans Pharma Quarterly Results for Trading Insights
In Sept 2025, Marksans Pharma (MARKSANS) reported revenue ₹742 Cr and net profit ₹99 Cr — revenue +15.6% YoY. For annual financials, live price and key ratios, visit MARKSANS share price screener.
MARKSANS Quarterly Results — Revenue, Profit & EPS Highlights
Marksans Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with MARKSANS fundamental valuation to assess whether the stock is under or overvalued.
- Revenue of ₹742 Cr in Sept 2025 (+2.5% vs Mar 2025, +15.6% vs Sept 2024)
- Net Profit of ₹99 Cr in Sept 2025 (+8.8% vs Mar 2025, +1.0% vs Sept 2024)
- EBITDA of ₹166 Cr in Sept 2025 (+16.9% vs Mar 2025)
- Operating Margin of 20.0% in Sept 2025 (+2.0pp vs Mar 2025)
- Earnings Per Share of ₹2.17 in Sept 2025 (+8.5% vs Mar 2025)
Marksans Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
MARKSANS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 742 | 724 | 626 | 775 | 642 | 2.5% | 15.6% |
| Net Profit (₹ Cr) | 99 | 91 | 58 | 114 | 98 | - | - |
| EBITDA (₹ Cr) | 166 | 142 | 106 | 181 | 147 | - | - |
| EPS (₹) | 2.17 | 2.00 | 1.29 | 2.50 | 2.13 | - | - |
| Operating Margin (%) | 20.0% | 18.0% | 16.0% | 21.0% | 23.0% | - | - |
MARKSANS Share Price Trend — 1-Year Movement Across Quarterly Results
Marksans Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore Marksans Pharma share price performance to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
MARKSANS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Marksans Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1844.3 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 163.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6797.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 240.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4537.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 394.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1418.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.4 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1319.0 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.7 |
All amounts in ₹ Crores